New York, New York (PRWEB) May 11, 2015
The federal court overseeing thousands of Actos bladder cancer lawsuits (http://www.theactoslawsuitcenter.com/) is preparing for the implementation of the proposed settlement program announced last month by Takeda Pharmaceutical Co. According to an Order issued on April 28th in the U.S. District Court, Western District of Louisiana, eligible plaintiffs and unfiled claimants who elect to participate in the settlement must submit an Opt-In Package to the Court no later than 11:59 p.m., CST, on July 13, 2015. Those who have opted into the program will then have 45 days from that deadline to submit a Claims Package seeking an award. (In re: Actos Product Liability Litigation, MDL No. 2299)
“Our Firm is representing numerous Actos lawsuit plaintiffs who are eligible to participate in this settlement, and we are in the process of evaluating the settlement proposal so that we can advise each of our individual clients on their best course of action,” says Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm continues to offer free legal evaluations to individuals who were treated with Actos for a year or more, and who allegedly went on to develop bladder cancer due to their use of the drug.
Actos Bladder Cancer Litigation
According to court documents, the multidistrict litigation underway in the Western District of Louisiana currently houses some 3,500 Actos lawsuits that were filed on behalf of individuals who allegedly developed bladder cancer due to their use of the Type 2 diabetes medication. The settlement program announced last month by Takeda could potentially resolves these claims, as well as thousands of others currently pending in state courts around the U.S. Eligible claimants includes Actos users who were treated with the medication prior to December 1, 2011, and who were diagnosed with bladder cancer before to August 28, 2015.
Court records indicate that Takeda will pay $2.37 billion into an Actos settlement fund if 95% of eligible plaintiffs agree to opt-in to the program. That amount increases to $2.4 billion if the opt-in rate reaches 97%. According to Bloomberg News, claimants could receive individual awards in excess of $296,000. However, that amount could be reduce by a number of factors, including a claimant’s age, history of smoking, or toxic exposures.*
Bernstein Liebhard LLP has updated its website with the most current information regarding the proposed Actos settlement. To learn more about filing an Actos lawsuit, and to arrange for a free, no-obligation review of your case, please visit the site or call 800-511-5092.
*bloomberg.com/news/articles/2015-04-28/takeda-said-to-agree-to-pay-2-3-billion-to-settle-actos-cases, Bloomberg News, April 28, 2015
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The National Law Journal has recognized Bernstein Liebhard for twelve consecutive years as one of the top plaintiffs' firms in the country. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2015 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Sandy A. Liebhard, Esq.
info (at) consumerinjurylawyers (dot) com